-
1.发明公开公开(公告)号：US20230365582A1
公开(公告)日：2023-11-16
申请号：US18042352
申请日：2021-08-20
Inventor： Young Sook SHIN , Sang Kyun LIM , Yeri LEE , Donggeon KIM , Soo Bong HAN , Chang Soo YUN , Hyun Jin KIM , Joo Youn LEE , Hyuk LEE , Sikwang SEONG
IPC: C07D495/04 , C07D333/24 , C07D333/38 , C07D409/10 , C07D409/06
CPC classification number: C07D495/04 , C07D333/24 , C07D333/38 , C07D409/10 , C07D409/06
Abstract: The present application relates to a novel compound having inhibitory activity on prostaglandin E2 receptor and uses thereof, and provides a compound represented by formula I, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a method of using the same.
-
公开(公告)号：US20230295258A1
公开(公告)日：2023-09-21
申请号：US18041392
申请日：2021-08-10
Applicant: KANAPH THERAPEUTICS INC.
Inventor： Donggeon KIM , Soomin RYU , Dahea LEE , Dongsu KIM , Jihoon CHANG , Byoung Chul LEE
CPC classification number: C07K14/5434 , C07K16/40 , A61P35/00 , C12N15/63 , C07K2317/565
Abstract: The present invention provides a bispecific antibody comprising IL-12 or a variant thereof and an antigen binding site that specifically binds to FAP. The bispecific antibody exhibits an anticancer effect by IL-12. In particular, when the anti-FAP antibody is implemented in one antibody, cancer may be efficiently treated by specifically targeting FAP expressed highly in a tumor, and specifically localizing IL-2 to the tumor site. Therefore, the bispecific antibody may be utilized as a pharmaceutical composition for anticancer treatment, and thus has high industrial application potential.
-
3.发明公开公开(公告)号：US20230242633A1
公开(公告)日：2023-08-03
申请号：US18004613
申请日：2021-07-07
Applicant: KANAPH THERAPEUTICS INC.
Inventor： Eu Ddeum CHUNG , Soomin RYU , Donggeon KIM , Jihoon CHANG , Byoung Chul LEE
IPC: C07K16/22 , C07K14/705 , A61P27/02
CPC classification number: C07K16/22 , C07K14/70503 , A61P27/02 , C07K2319/30
Abstract: Provided is a fusion protein dimer containing an extracellular domain of CRIg or a fragment thereof, and a protein that specifically binds to VEGF. The protein may not only inhibit complement-related pathways, but also effectively modulate angiogenesis. Therefore, the fusion protein dimer may be effectively used for the treatment and prevention of complement-related diseases, specifically, eye diseases such as macular degeneration, and thus a high possibility of being industrially used.
-
公开(公告)号：US20250144178A1
公开(公告)日：2025-05-08
申请号：US18836703
申请日：2023-02-10
Applicant: KANAPH THERAPEUTICS INC.
Inventor： Dongsu Kim , Donggeon Kim , Hyunji Lee , Yujin Yoon , Youngin Lee , Dahea Lee , Jihoon Chang , Byoung Chul Lee
IPC: A61K38/20 , A61K31/337 , A61K31/4745 , A61K31/513 , A61K31/675 , A61K39/00 , A61K39/395 , A61P35/00
Abstract: The present invention provides a combined therapeutic agent of: a fusion protein comprising IL-12 or a variant thereof and an antigen-binding site that specifically binds to FAP; and an anticancer agent. The bispecific antibody exhibits an anticancer effect by IL-12 and in particular, when the anti-FAP antibody is realized in one antibody, cancer can be efficiently treated by targeting FAP expressed highly specifically in a tumor and specifically localizing IL-12 to a tumor site. When the fusion protein is administered in combination with a known anticancer agent, there is a synergistic effect on anticancer treatment.
-
公开(公告)号：US20240400518A1
公开(公告)日：2024-12-05
申请号：US18684629
申请日：2022-08-17
Applicant: KANAPH THERAPEUTICS INC. , CYRUS THERAPEUTICS INC.
Inventor： Ha Na YU , Young Sook SHIN , Dohyun PARK , Kyeong Jin YOON , Sang Kyun LIM , Donggeon KIM , Dong Hyuk KI , Eun-Jung KIM , Joonwoo NAM , Wooseok HAN , Jihyun YU , Ji Eun KIM
IPC: C07D231/22 , A61K31/4418 , A61K31/4965 , A61K31/501 , C07D213/87 , C07D241/24
Abstract: There is provided a novel compound of Formula I and a use thereof for the prevention or treatment of a disease associated with SOS1. In one aspect of the present invention, the novel compound is useful for the prevention or treatment of a SOS1 mediated disease such as cancer and RASopathy by inhibiting the interaction between SOS1 and RAS family proteins or between SOS1 and RAC1.
-
Patent Agency Ranking
公开(公告)号：US20250161271A1
公开(公告)日：2025-05-22
申请号：US18838591
申请日：2023-02-15
Inventor： Donggeon KIM , Yeri LEE , Sang Kyun LIM , Young Sook SHIN , Soo Bong HAN , Chang Soo YUN , Hyuk LEE , Hyun Jin KIM , Joo Youn LEE , Si Kwang SEONG , Taeyoung YOON , Youngrae LEE
IPC: A61K31/407 , A61K31/381 , A61K31/397 , A61K31/4155 , A61K31/4436 , A61K31/4535 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P35/00
Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising a novel compound that inhibits the activity of prostaglandin E2 receptor and an anticancer agent as active ingredients. The novel compound of the present invention inhibited the activity of prostaglandin E2 receptor and inhibited tumor growth in colorectal cancer and lung cancer tumor models. In addition, it was found that when administered in combination with other anticancer agents such as a chemotherapeutic agent and/or an immune checkpoint inhibitor, a synergistic effect was exhibited in anticancer activity. Therefore, a pharmaceutical composition for treating cancer, comprising the novel compound and an anticancer agent as active ingredients may be effectively used for the prevention and treatment of cancer.
-
公开(公告)号：US20250074974A1
公开(公告)日：2025-03-06
申请号：US18726333
申请日：2022-12-27
Applicant: Kanaph Therapeutics Inc.
Inventor： Eu Ddeum Chung , Soomin Ryu , Donggeon Kim , Jihoon Chang , Byoung Chul Lee
Abstract: The present invention relates to a fusion protein comprising an anti-C3b antibody or an anti-C5 antibody and an angiogenesis inhibitor, and a composition for treating eye diseases, particularly macular degeneration, by using the same. The protein may not only inhibit complement-related pathways, but can also efficiently regulate angiogenesis. Therefore, the fusion protein dimer can be effectively used to treat and prevent complement-related diseases, particularly eye diseases such as macular degeneration, and thus has high industrial applicability.
-
公开(公告)号：US12029739B2
公开(公告)日：2024-07-09
申请号：US18407400
申请日：2024-01-08
Applicant: KANAPH THERAPEUTICS INC.
Inventor： Miyeon Kim , Dohyun Park , Dongsu Kim , Kyeongjin Yoon , Sungpil Choi , Sang Kyun Lim , Eu Ddeum Chung , Mijung Lee , Dahye Jeon , Soyeon Jang , Kyungik Lee , Jinhwan Kim , Eunji Kim , Jieun Min , Kangwoo Lee , Jakyung Yoo
IPC: A61K31/497 , A61K31/506 , A61K31/517 , A61K31/53 , A61K31/551 , C07D401/04 , C07D401/14 , C07D405/14 , C07D471/10 , C07D491/107 , C07D519/00
CPC classification number: A61K31/497 , A61K31/506 , A61K31/517 , A61K31/53 , A61K31/551 , C07D401/04 , C07D401/14 , C07D405/14 , C07D471/10 , C07D491/107 , C07D519/00
Abstract: The present invention relates to an inhibitor of SHP2, a pharmaceutical composition for preventing or treating a disease related to SHP2 comprising the same, a method for treating and preventing a disease using the same, and a use thereof. Accordingly, the present invention can effectively prevent or treat diseases related to SHP2.
-
公开(公告)号：US20240189306A1
公开(公告)日：2024-06-13
申请号：US18407400
申请日：2024-01-08
Applicant: KANAPH THERAPEUTICS INC.
Inventor： Miyeon KIM , Dohyun PARK , Dongsu KIM , Kyeongjin YOON , Sungpil CHOI , Sang Kyun LIM , Eu Ddeum CHUNG , Mijung LEE , Dahye JEON , Soyeon JANG , Kyungik LEE , Jinhwan KIM , Eunji KIM , Jieun MIN , Kangwoo LEE , Jakyung YOO
IPC: A61K31/497 , A61K31/506 , A61K31/517 , A61K31/53 , A61K31/551 , C07D401/04 , C07D401/14 , C07D405/14 , C07D471/10 , C07D491/107 , C07D519/00
CPC classification number: A61K31/497 , A61K31/506 , A61K31/517 , A61K31/53 , A61K31/551 , C07D401/04 , C07D401/14 , C07D405/14 , C07D471/10 , C07D491/107 , C07D519/00
Abstract: The present invention relates to an inhibitor of SHP2, a pharmaceutical composition for preventing or treating a disease related to SHP2 comprising the same, a method for treating and preventing a disease using the same, and a use thereof. Accordingly, the present invention can effectively prevent or treat diseases related to SHP2.
-
公开(公告)号：US20230295327A1
公开(公告)日：2023-09-21
申请号：US18040632
申请日：2021-08-10
Applicant: KANAPH THERAPEUTICS INC.
Inventor： Dahea LEE , Soomin RYU , Donggeon KIM , Jihoon CHANG , Byoung Chul LEE
CPC classification number: C07K16/2887 , C07K14/5434 , A61P35/00 , C12N15/63 , C07K2317/565 , C07K2317/622 , C07K2317/522
Abstract: The present invention provides a bispecific antibody comprising IL-12 or a variant thereof and an antigen binding site that specifically binds to CD20. The bispecific antibody exhibits an anticancer effect by IL-12. In particular, when the anti-CD20 antibody is implemented in one antibody, IL-12 is specifically localized to a tumor site by targeting CD20, which is specifically expressed in a tumor at a high level, thereby efficiently treating cancer. Therefore, the bispecific antibody can be utilized as a pharmaceutical composition for anticancer treatment, and thus has a high potential for industrial application.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.02 seconds)
